US · ABBV
AbbVie Inc.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- North Chicago, IL 60064-6400
- Website
- abbvie.com
Price · as of 2025-12-31
$206.60
Market cap 410.09B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $161.09 | -22.03% |
| Intrinsic Value(DCF) | $105.73 | -48.82% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $38.60 | -81.32% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $14.23 | $40.84 | |||
| 2012 | $22.50 | $57.65 | $14.20 | $14.97 | $44.47 |
| 2013 | $31.96 | $53.94 | $13.11 | $0.00 | $26.59 |
| 2014 | $37.75 | $47.04 | $1.54 | $0.00 | $15.64 |
| 2015 | $37.84 | $60.63 | $52.68 | $0.00 | $69.94 |
| 2016 | $45.22 | $64.89 | $56.79 | $0.00 | $72.67 |
| 2017 | $83.96 | $79.99 | $59.43 | $0.00 | $58.86 |
| 2018 | $57.86 | $71.78 | $32.12 | $0.00 | $86.48 |
| 2019 | $66.85 | $105.00 | $34.56 | $0.00 | $51.42 |
| 2020 | $91.06 | $108.61 | $278.37 | $0.00 | $122.10 |
| 2021 | $131.47 | $129.71 | $383.37 | $0.00 | $193.98 |
| 2022 | $136.34 | $128.91 | $264.31 | $0.00 | $76.07 |
| 2023 | $167.69 | $121.68 | $10.03 | $0.00 | $5.53 |
| 2024 | $209.63 | $141.28 | $0.07 | $0.00 | $28.45 |
| 2025 | $234.26 | $161.09 | $9.47 | $0.00 | $38.60 |
AI valuation
Our deep-learning model estimates AbbVie Inc.'s (ABBV) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $161.09
- Current price
- $206.60
- AI upside
- -22.03%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$105.73
-48.82% upside
Graham-Dodd
—
— upside
Graham Formula
$38.60
-81.32% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ABBV | AbbVie Inc. | $206.60 | 410.09B | -22% | -49% | — | -81% | 99.26 | -128.28 | 6.86 | 17.08 | — | -4.58 | 83.71% | 34.69% | 6.91% | 15367.27% | 21.58% | 3.14% | -21.12 | 8.08 | 0.67 | 0.41 | 2.26 | -126.00% | 857.00% | -9.00% | 4.25% | 0.44 | 28.25% | 2.78% | 275.80% | 3.01% | 22.78 | 27.13 | 7.90 | 2.52 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| AZN | AstraZeneca PLC | $208.45 | 646.31B | -44% | -57% | -100% | -74% | 61.77 | 12.98 | 10.75 | 33.06 | 32.62 | -60.60 | 81.90% | 23.40% | 17.46% | 22.86% | 16.43% | 9.38% | 0.61 | 8.11 | 0.94 | 0.68 | 1.21 | 18938.00% | 863.00% | 6172.00% | 1.86% | 0.48 | 17.05% | 0.80% | 49.70% | 1.02% | 47.70 | 55.72 | 11.16 | 6.83 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| JNJ | Johnson & Johnson | $248.43 | 598.69B | -22% | -48% | — | -38% | 22.52 | 7.40 | 6.41 | 15.83 | 24.88 | -34.24 | 72.78% | 27.17% | 28.46% | 35.03% | 21.82% | 14.13% | 0.59 | 26.36 | 1.03 | 0.69 | 0.71 | 9050.00% | 605.00% | -73.00% | 3.26% | 0.45 | 20.41% | 2.05% | 46.20% | 3.04% | 24.67 | 32.06 | 6.70 | 5.17 |
| MRK | Merck & Co., Inc. | $123.78 | 306.03B | +5% | -27% | -61% | -44% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| NVO | Novo Nordisk A/S | $37.45 | 166.46B | +59% | +7% | — | -3% | 10.46 | 5.52 | 3.60 | 8.17 | 591.70 | 16.74 | 80.34% | 43.69% | 33.14% | 60.70% | 39.34% | 20.31% | 0.67 | 19.92 | 0.80 | 0.48 | 0.73 | 177.00% | 234.00% | -5838.00% | 2.71% | 0.55 | 11.19% | 4.65% | 48.60% | 4.77% | 9.05 | 40.54 | 3.95 | 3.59 |
| NVS | Novartis AG | $168.62 | 325.95B | -29% | -50% | — | -40% | 23.02 | 7.01 | 5.90 | 15.18 | 102.37 | -36.57 | 75.02% | 31.15% | 25.64% | 31.17% | 21.84% | 12.91% | 0.80 | 14.38 | 1.12 | 0.83 | 1.11 | 2249.00% | 597.00% | 2811.00% | 5.47% | 0.71 | 26.49% | 2.43% | 55.90% | 5.29% | 20.44 | 19.73 | 6.37 | 4.35 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| UNH | UnitedHealth Group Incorp… | $293.27 | 265.66B | -28% | +144% | -84% | -12% | 20.96 | 2.68 | 0.60 | 13.82 | — | 2.68 | 18.53% | 4.24% | 2.69% | 13.29% | 11.37% | 4.21% | 0.78 | 4.74 | 0.79 | 0.45 | 2.18 | -1470.00% | 1181.00% | -2236.00% | 5.99% | 0.17 | 11.06% | 2.95% | 61.80% | 5.51% | 16.80 | 19.82 | 0.71 | 2.33 |
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- CEO
- Robert A. Michael
- Employees
- 55K
- Beta
- 0.33
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($105.73 ÷ $206.60) − 1 = -48.82% (DCF, example).